Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The majority of patients experience significant weight regain if treatment with GLP-1 medications stops, and it is unclear if there will be a sustainable, long-term access to GLP-1 treatment for obesity for Medicare beneficiaries. Nielsen says she anticipates demand for the GLP-1 Bridge program will be high, making it important to see your healthcare provider for an evaluation now
These logistical factors increase operational costs and are reflected in pricing
*Correspondence: Mohammed Mahmmoud Fadelallah Eljack, [email protected] ORCID: Bisma Fatima Hammad, orcid.org/0000-0001-5558-3889
Aon theorized that, by losing weight, patients started accessing a broader range of other medical treatments
Mounjaro (May 2022) is approved for type 2 diabetes, helping control blood sugar while also supporting weight loss
